Other indications

International registry on the use of the CytoSorb(R) adsorber in ICU patients : Study protocol and preliminary results.

Friesecke S, Trager K, Schitter GA, Molnar Z, Bach F, Kogelmann K, Bogdanski R, Weyland A, Nierhaus A, Nestler F, Olboeter D, Tomescu D, Jacob D, Haake H, Grigorjev E, Nitsch M, Baumann A, Quintet M, Schott M, Kielstein JT, Meier-Hellmann A, Born F, Schumacher U, Singer M, Kellum J, Brunkhorst FM.
Med Klin Intensivmed Notfallmed 2017; epub

This is the third interim analysis from the CytoSorb clinical registry where the aim is...

This is the third interim analysis from the CytoSorb clinical registry where the aim is to record the use of CytoSorb adsorbers in critically ill patients under real-life conditions. It records all relevant information in the course of product use, including diagnosis, comorbidities, course of the condition, treatment, concomitant medication, clinical laboratory parameters, and outcome. Data available from the start of the registry on May 18, 2015 to November 24, 2016 (122 centers; 22 countries) were analyzed, of whom 20 centers from four countries provided data for a total of 198 patients (mean age 60.3 +/- 15.1 years). In all, 192 (97.0%) had 1 to 5 Cytosorb(R) adsorber applications. Sepsis was the most common indication for CytoSorb(R) treatment (135 patients). Mean APACHE II score in this group was 33.1 +/- 8.4 [range 15-52] with a predicted risk of death of 78%, whereas the observed mortality was 65%. There were no significant decreases in the SOFA scores after treatment, however interleukin-6 levels were markedly reduced after treatment (median 5000 pg/ml before and 289 pg/ml after treatment, respectively). This third interim report demonstrates the feasibility of the registry with excellent data quality and completeness from 20 study centers. Patient numbers are still small; however the disease severity is remarkably high and suggests that adsorber treatment might be used as a potentially beneficial treatment in life-threatening situations. Treating physicians rated the condition of the patients as much or very much improved in approximately 50% of cases and reported a very favorable safety profile with no device-associated side effects.

International registry on the use of the CytoSorb-Adsorber in ICU patients (NCT02312024)

Schein M, Bahr V, Rissner F, Jakob M, Schumacher U, Brunkhorst FM
Infection. 2015 Aug;43Suppl 1:1-73. Abstract No. 125

This article gives an overview on the objectives and methods of the currently implemented international...

This article gives an overview on the objectives and methods of the currently implemented international CytoSorb registry.

Feasibility study of cytokine removal by hemoadsorption in brain-dead humans

Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M
Crit Care Med. 2008 Jan;36(1):268-72

Through numerousmechanisms, brain death is associatedwith a massive release of proinflammatory cytokines, detectable both in...

Through numerousmechanisms, brain death is associatedwith a massive release of proinflammatory cytokines, detectable both in blood and transplantable organs. This increased inflammatory response has been associated withpoor allograft function before and after transplantation. Therefore, this in vivo study examines the feasibility of hemoadsorption (using CytoSorb) to remove cytokines in brain-dead humans (n=8).